{"product_id":"xers-bcg-matrix","title":"(XERS) Xeris Biopharma Holdings, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Xeris Biopharma Holdings, Inc. BCG Matrix is a company-specific tool for quickly understanding how its products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework. The page already shows a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke is Xeris Biopharma Holdings, Inc.'s clearest Star: a ready-to-administer liquid glucagon for severe hypoglycemia in the core diabetes rescue franchise. It stays a key growth driver because it solves a real emergency-use problem better than reconstituted glucagon kits.\u003c\/p\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. said Gvoke generated $60.7 million in 2024 net product revenue, up 12% year over year, showing continued commercial traction.\u003c\/p\u003e\n\u003cp\u003eThat mix of strong growth and franchise fit supports its Star position in the BCG Matrix, with room to keep scaling if diabetes rescue adoption keeps rising.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke HypoPen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke HypoPen is a Star for Xeris Biopharma Holdings, Inc. because its autoinjector format is fast, simple, and built for emergencies. The device-led design helps Xeris win shelf space and grow visibility in the glucagon rescue market, where ease of use matters most. It is one of the portfolio’s most consumer-facing assets and a key driver of brand pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke PFS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke PFS extends Gvoke into a second ready-to-use format, alongside HypoPen, with 2 dose strengths: 0.5 mg and 1 mg. That breadth helps Xeris Biopharma Holdings, Inc. keep the brand visible in a rescue market where speed and ease of use matter. It supports follow-on prescribing and helps defend share as glucagon rescue use expands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRecorlev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecorlev is Xeris Biopharma Holdings, Inc.’s oral cortisol synthesis inhibitor for endogenous hypercortisolemia in adults with Cushing’s syndrome. It targets a rare, high-need market, so the long runway is real, but the product is still in a build phase and needs steady launch support and doctor adoption to scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease focus supports pricing power.\u003c\/li\u003e\n\u003cli\u003eOral dose can aid patient convenience.\u003c\/li\u003e\n\u003cli\u003eBuild phase means SG\u0026amp;A stays elevated.\u003c\/li\u003e\n\u003cli\u003eGrowth depends on specialist uptake.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXeriSol and XeriJect\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeriSol and XeriJect are Xeris Biopharma Holdings, Inc.’s core formulation platforms, so they sit in the \"Stars\" bucket because they can keep feeding new injectable and rescue-style products into the pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary platform tech\u003c\/li\u003e\n\u003cli\u003eSupports branded asset creation\u003c\/li\u003e\n\u003cli\u003eUseful for future launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe real value is leverage: one platform can lower development friction across multiple programs and extend Xeris Biopharma Holdings, Inc.’s reach beyond single products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke Drives Xeris Growth as Recorlev Builds Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGvoke remains Xeris Biopharma Holdings, Inc.'s main Star: 2024 net product revenue was $60.7 million, up 12% year over year, and its ready-to-use rescue design keeps demand strong in severe hypoglycemia. Recorlev adds a second growth engine in rare disease, but it is still earlier in scale-up.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003e2024 revenue\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003e$60.7M\u003c\/td\u003e\n\u003ctd\u003e12% growth; rescue use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003eLaunch phase\u003c\/td\u003e\n\u003ctd\u003eRare disease upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eXeris Biopharma’s BCG Matrix maps its portfolio to spot growth bets, cash generators, and potential divestitures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix view of Xeris Biopharma to pinpoint winners, drags, and capital priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Xeris Biopharma Holdings, Inc., helping investors verify key claims and make faster, better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeveyis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeveyis is Xeris Biopharma Holdings, Inc.'s most mature rare-disease asset, with repeat use in primary periodic paralysis, an ultra-rare disorder that affects about 1 in 100,000 people. That small but defined patient pool makes demand steady, so Keveyis behaves like a cash cow inside the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary periodic paralysis franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.'s primary periodic paralysis franchise fits \"Cash Cow\" status because it serves an ultra-rare chronic setting with limited competition, so demand is steadier than a broad primary-care launch. Xeris Biopharma Holdings, Inc. does not need heavy population-building, which helps keep promotion spend lower and margins more predictable. That kind of niche, repeat-use market usually throws off reliable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan refill base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeveyis is a long-term orphan therapy for primary periodic paralysis, so patients usually stay on treatment and refill it over time. That creates a predictable replenishment loop, which fits the classic cash-cow pattern in a small market. Repeated chronic use can support steady revenue with low share loss once patients are stabilized on therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished specialty pharmacy channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. uses established specialty pharmacies to reach rare and complex therapy patients, so mature brands can add sales without building much new field or distribution cost. In 2025, that setup helped support margin control as the channel was already in place.\u003c\/p\u003e\n\u003cp\u003eThis is a Cash Cow because the channel is sticky, targeted, and built for chronic specialty use. Once access, onboarding, and refill paths are set, each extra prescription tends to need less new spending than a new launch.\u003c\/p\u003e\n\u003cp\u003eThe result is steadier cash flow from brands like Gvoke and Recorlev, with less pressure on SG\u0026amp;A (selling, general, and administrative expense) as volumes rise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilt specialty access lowers growth cost\u003c\/li\u003e\n\u003cli\u003eRepeat fills support stable revenue\u003c\/li\u003e\n\u003cli\u003eMature brands can protect margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMature rare-disease support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.'s Keveyis sits in the cash-cow bucket because its rare-disease support network is already built, so the business can keep generating revenue without heavy launch spend. That matters in a small niche: once the patient support, reimbursement, and field setup are in place, the model is far cheaper to run than a new launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting support lowers incremental costs.\u003c\/li\u003e\n\u003cli\u003eKeveyis needs less launch investment now.\u003c\/li\u003e\n\u003cli\u003eRare-disease demand is steady, niche, and durable.\u003c\/li\u003e\n\u003cli\u003eThat makes the asset a cash generator.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeveyis: Xeris’ Small but Steady Cash Cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeveyis is Xeris Biopharma Holdings, Inc.'s clearest cash cow: primary periodic paralysis affects about 1 in 100,000 people, so demand is small but recurring. With specialty access already in place in 2025, Xeris Biopharma Holdings, Inc. can keep refills flowing without heavy launch spend, which helps support cash generation.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eXeris Biopharma Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Xeris Biopharma Holdings, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages or placeholder content—just the complete, professionally formatted report.\u003c\/p\u003e\n\u003cp\u003eOnce purchased, the full file is instantly available for download and ready to use for analysis, presentation, or strategy work. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy non-core programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc. runs a portfolio centered on 3 marketed products, so legacy non-core programs fit the Dogs bucket: low share, low growth, and little sales pull. In 2025, these older assets can still drain R\u0026amp;D and G\u0026amp;A cash without moving revenue, making them candidates for pruning, partnering, or quiet wind-down.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly discovery assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.'s early discovery assets sit in the dog zone because they are pre-revenue and have near-zero market share until they reach proof of concept. As of the latest filing, Xeris still spent heavily on R\u0026amp;D while these programs stayed cash-consuming, so the return stays weak unless they advance. If traction does not show up soon, they remain a drag on capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePaused or slowed pipeline work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePaused pipeline work can be a clear Dog for Xeris Biopharma Holdings, Inc. because every stalled program still consumes R\u0026amp;D staff, lab time, and cash while adding little near-term value. In small-cap biopharma, management usually trims or stops such projects fast, since Xeris posted just $195.9 million in 2024 net product revenue and cannot afford long capital lockups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-revenue internal projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris Biopharma Holdings, Inc.’s non-revenue internal projects fit \"Dogs\" in BCG terms when they have $0 product sales and no clear scale path, so they do not add operating cash flow. In FY2025, Xeris still relied on commercial products, so any project that stays pre-revenue and cannot scale is a pruning candidate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero sales, zero cash flow\u003c\/li\u003e\n\u003cli\u003eNo scale path, weak fit\u003c\/li\u003e\n\u003cli\u003ePrune or pause fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall low-growth support items\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall support items at Xeris Biopharma Holdings, Inc. fit the dog profile: in a mature, narrow niche, they add little upside and tie up effort that rarely lifts returns. If the addressable market is tiny and growth stays low, ROI stays weak, so these items are better seen as cash-drain fillers than growth engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTiny market\u003c\/li\u003e\n\u003cli\u003eLow growth\u003c\/li\u003e\n\u003cli\u003eWeak ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris’ Dogs: 3 Marketed Products, Low Growth, High Drag\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at Xeris Biopharma Holdings, Inc. are the non-core, pre-revenue or paused programs that still consume R\u0026amp;D and G\u0026amp;A but add little near-term sales. With only 3 marketed products, these assets stay low-share, low-growth, and are best trimmed, partnered, or wound down.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDogs signal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed products\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePaused\/pre-revenue assets\u003c\/td\u003e\n\u003ctd\u003e$0 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital use\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\/G\u0026amp;A drag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecorlev expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecorlev is still a growth asset, not a mature cash cow, because Cushing’s syndrome is rare and broader use still depends on physician education and tighter diagnosis. Xeris Biopharma Holdings, Inc. will need to keep funding promotion and access work; if penetration rises, Recorlev can move from question mark toward star status. The key test is faster prescription growth, not just approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew glucagon indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke has a solid base in rescue care, with 2 approved strengths, 0.5 mg and 1 mg, but new glucagon uses still look like a question mark. If Xeris Biopharma Holdings, Inc. wins a label expansion or wider clinical use, it could lift share in a niche that is still very focused on severe hypoglycemia. If not, growth can level off.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric rescue growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatric rescue growth is still early for Xeris Biopharma Holdings, Inc. Gvoke is already approved for children 2 years and older, so broader use in younger patients could widen the glucagon pool. But adoption still needs education, payer pull, and clean execution, which fits a question mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXeriSol pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeriSol is Xeris Biopharma Holdings, Inc.’s injectable formulation engine, and its pipeline fits a question mark in the BCG Matrix: the platform can launch new products, but most value is still future-facing. In 2025, Xeris still had no disclosed standalone market share for XeriSol pipeline assets, so growth potential is clear, but cash contribution is not yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh future upside\u003c\/li\u003e\n\u003cli\u003eLow current market share\u003c\/li\u003e\n\u003cli\u003ePipeline value not yet monetized\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXeriJect pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeriJect fits the Question Marks box because it is a platform asset with upside, but its new branded candidates have not yet proven market leadership. Xeris must keep funding clinical, launch, and commercial work to move them from early traction to scale. Until that happens, the pipeline remains a cash user with uncertain share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh potential, low proven share\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNeeds ongoing investment\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCan become a Star if launches win\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris’ Growth Bets Still Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks at Xeris Biopharma Holdings, Inc. are still growth bets: Recorlev, Gvoke expansion, pediatric rescue, and XeriSol\/XeriJect need more proof before they can act like Stars. In FY2025, Gvoke still had just 2 approved strengths, 0.5 mg and 1 mg, and the pediatric label starts at age 2, so share gains still depend on spend, access, and education.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003eRare Cushing's use\u003c\/td\u003e\n\u003ctd\u003eQuestion mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003e0.5 mg, 1 mg\u003c\/td\u003e\n\u003ctd\u003eQuestion mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXeriSol\/XeriJect\u003c\/td\u003e\n\u003ctd\u003eNo standalone share disclosed\u003c\/td\u003e\n\u003ctd\u003eQuestion mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235212763401,"sku":"xers-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/xers-bcg-matrix.webp?v=1785736472","url":"https:\/\/dcfanalyst.com\/products\/xers-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}